VERO Biotech Inc. – an Atlanta, Georgia-based company focused on saving lives, alleviating suffering, and improving the health economics of care – was awarded the prestigious Golden Helix “Innovation Award” for its breakthrough development of the GENOSYL® Delivery System, the first advancement in the delivery of inhaled nitric oxide in 20 years, and the “Deal of the Year” Award for 2022 by Georgia Bio, the state’s life science trade association.

Checkpoint inhibitor pioneer James P. Allison, who won the 2018 Nobel Prize in Medicine, will helm a new research and innovation hub at The University of Texas MD Anderson Cancer Center that is focused on developing new immunotherapy breakthroughs in oncology.

As the health industry rapidly shifts to more patient-centric approaches to care and clinical research, technology is just as quickly becoming the cornerstone to effectively engage clinical study participants. Electronic clinical outcome assessments (eCOAs) are essential to ensuring that each clinical trial is optimized for the patient’s experience by being faster, more on-demand, and more customizable. Kris Gustafson – Vice President and Global Head IQVIA eCOA, IQVIA – discusses three key reasons to implement an eCOA strategy for clinical trials.

Medable Inc., the leading software provider for patient-centered clinical trials, launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials.

epocrates, an athenahealth Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company recently brought on Matt Titus – an industry veteran of 13 years – to serve as the organization’s vice president, chief commercial officer.

The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030.

Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.

Honeycomb Health, a project being created out of Greater Than One’s nonprofit subsidiary GTO Greater Good, was named a finalist in the Top 8 That Innovate. The Top 8 were selected by a panel of pharmaceutical and biotech companies that are members of the Diversity Alliance for Science.

Dr. Bethany Valente, founder and managing partner of Tempo7 LLC, discusses the challenges that biotech and pharma-based businesses face as they work to create more efficient development time frames for product, therapy, or drug development. Dr. Valente says open innovation helps in resolving some of these challenges.

Two very exciting areas where Artificial Intelligence (AI) is having an impact on the life sciences landscape are patient stratification and synthetic control arms. Recent data and technology advances are starting to yield compelling results, according to Derek Baird, President North America of Sensyne Health and Commercial Director of SENSE.